XCures Inc., an artificial intelligence-assisted cancer patient treatment insights platform, today announced that it raised $12.69 million in an early-stage funding round.

The Series A round was led by science-focused Boehringer Ingelheim Venture Fund and joined by Vanedge Capital, Harmonix Fund and Metaplanet.

The xCures platform takes unstructured medical data from patient records and turns it into machine-readable data that can be digested by artificial intelligence algorithms. It is then fed into a vast pool of data and used for predictive modeling sets to help patients receive better care and outcomes related to cancer treatments.

The AI then acts as an expert agent that sifts through that vast archive of data and cross-references patient medical data to narrow down likely treatments and clinical trials that helped other patients with similar cancers and offers those as insights.

“This new investment enables us to leverage our experience in helping over 1,000 patients on our platform to dramatically increase both platform usage and the insights we are generating,” said xCures Chief Executive Mika Newton.

The platform assists both patients and physicians in making important decisions for treatments based on medical records, with two different portals designed to address both audiences: xInform and xAccess.

XInform speaks to patients by using AI-powered clinical data to help them understand the most promising treatments based on expert-sourced insights. Meanwhile, xAccess expands on xInform’s scope and uses natural language processing on medical records and other clinical studies to provide oncologists with clinical decision support tools.

Because the system digests the patient’s entire medical history from raw data, it also provides physicians and patients a way to review their current plan and historical “Cancer Journey” of their current treatment on an easy-to-understand dashboard. All of the real-world data acquired this way from patients remains private and stored compliant with U.S. laws such as the Health Insurance Portability and Accountability Act.

The platform also supplies biopharmaceutical research companies with data based on real-world evidence to create new therapies for treating cancers.

“The Boehringer Ingelheim Venture Fund sees the potential of the xCures platform to provide valuable options for advanced cancer patients, while at the same time generating real-world evidence that could lead to important therapeutic insights,” said Mark Ralph, executive director of the Boehringer Ingelheim Venture Fund.

Image: Pixabay